Sponsored Content
Most Unique Holiday Tech Gifts for 2025
Before you reach for the obvious gift Every year, the holiday rush pushes us toward the same decisions. The safe ones. Earbuds that will be unwrapped, nodded at, and quietly added to a drawer. Watches that replace last year’s watch. Phones that feel more like a chore than a gift. This year, Tech Santa suggests a…
Xfinity Outage Reveals the Fragile Internet We Depend On
The morning of the Xfinity outage felt strangely familiar to anyone who has lived through a sudden internet blackout. One moment, everything worked. The next moment, nothing did. Video calls froze. Schoolwork stalled. Smart devices stopped responding. Even the usual background noise of notifications disappeared. The silence said everything. Our connected lives stop the moment the internet…
Figure AI’s $1 Billion Milestone: Humanoid Hype or Real Business?
Factories are usually the last place swept up by hype. Production floors reward consistency, not spectacle. Yet a robotics startup with limited large-scale deployment is now valued like an established industrial giant. The Figure AI valuation has convinced many executives that general-purpose robots shaped like people might become a future labour category. That belief is…
AWS RoboMaker Shutdown: Why Cloud Robotics Simulation Failed
Right now, a lot of robotics teams are quietly celebrating something odd: one less cloud tool to maintain. That’s the unexpected mood around the AWS RoboMaker shutdown, a move that surprised almost no one in robotics engineering circles, yet raised eyebrows across IT and cloud leadership. RoboMaker was supposed to bring robotics into the cloud era. Instead, it became a case study in how…
How the Rethink Robotics Collapse Became an Industry Signal
The robotics world gave Rethink Robotics a kind of reverence normally reserved for breakthrough companies. Baxter and Sawyer were treated as symbols of the future: friendly cobot helpers designed to bring automation to factories that could not afford traditional robots. They promised flexibility, safety, and fast payback. Then the Rethink Robotics collapse happened. Twice. If you work…
Antonio Stark: The Space Strategist Shaping a Shared Future Beyond Earth
In conversation with a global space visionary, explorer, and educator helping chart humanity’s next chapter beyond Earth. Space Visionaries: Minds Shaping Humanity’s Next Frontier: In an era where exploration stretches beyond Earth, this series spotlights the thinkers, explorers, and architects redefining our place in the cosmos. These are the voices building bridges between science and…
When Enterprise AI Agents Team Up with Themselves
The Multi-agent Enterprise Inside a large operations room, a workflow that once crawled across three human teams now runs on a quiet set of scripts. A research agent pulls data, a checker agent looks for gaps, a compliance agent formats the output, and a final supervisor agent signs off or escalates. The tickets still close….
Solving the AI Data Center Energy Dilemma with SMRs
Nuclear power’s AI-driven comeback AI is supposed to optimise everything. Yet it’s now the reason power grids are cracking under demand. Across the globe, hyperscalers are hitting a wall, the AI data center energy dilemma, where model training and 24/7 inference workloads devour electricity faster than grids can expand or renewables can compensate. So, tech giants are turning to something long considered untouchable: nuclear power. Not…
AI Romantic Relationships: When Bots are Choose Over Humans
A 39-year-old Michigan man thought he had finally found someone patient, attentive, and impossible to disappoint. She remembered everything he shared and never made him guess how she felt. There was just one detail he couldn’t ignore: she was an AI. This is where AI romantic relationships begin to shift the emotional landscape, offering a connection that feels safe,…
GLP-1 Drugs Second Act: Weight Loss to Brain Health
The GLP-1 drugs everyone’s been obsessed with for weight loss may turn out to be far more powerful than expected. Ozempic, Wegovy, and Saxenda, these GLP-1 weight-loss drugs, originally developed as GLP-1 diabetic medications, are now in major clinical trials to evaluate whether they can slow the progression of Alzheimer’s and Parkinson’s. And the early…